化β-粉样蛋白作为脑粉样血管病变的生物标志物
Emma van den Berg1, Iris Kersten1, Gunnar Brinkmalm2,3
1Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
Journal of neurochemistry
|February 16, 2024
概括
对粉样β (Aβ) 的脑脊液 (CSF) 分析可以区分脑粉样血管病变 (CAA) 和阿尔茨海默病 (AD) 病理学. 在CSF中较短的Aβ的CAA下降,这表明Aβ积累的独特机制.
科学领域:
- 神经学 神经学
- 生物化学 生化学
- 病理学 病理学 病理学
背景情况:
- 大脑粉样蛋白-β (Aβ) 沉积物是大脑粉样蛋白血管病变 (CAA) 和阿尔茨海默病 (AD) 的核心.
- CAA的特点是微血管Aβ沉积物 (主要是Aβ40),而AD涉及对酶体斑块 (主要是Aβ42).
- 其他Aβ异型在CAA病原和诊断中的作用还未得到充分研究.
研究的目的:
- 研究大脑脊髓液 (CSF) 中各种Aβ异型体的生物标志物潜力.
- 为了区分CAA与AD病理,使用CSF Aβ配置文件.
- 为了分析Aβ1-34,Aβ1-37,Aβ1-38,Aβ1-39,Aβ1-40和Aβ1-42的CSF水平.
主要方法:
- 包括25名可能的CAA患者,50名类似AD的CSF个人资料受试者和23名对照.
- 使用液态染色体质谱学量化六种CSF Aβ的量化.
- 统计分析以比较Aβ水平并评估诊断准确度 (AUC).
主要成果:
- 与对照组相比,在CAA患者中,所有六种Aβ的CSF水平都较低.
- 除Aβ1-42外,所有的CAA都降低,而非AD类受试者.
- 一个Aβ的组合小组显示高精度 (AUC 0.84) 在区分CAA与AD类受试者.
结论:
- 对于CAA和AD类病理,存在不同的CSF Aβ配置文件.
- 在CAA中比Aβ1-42短的Aβ的水平降低表明独特的血管Aβ积累机制.
- 脑液Aβ板显示出准确的CAA诊断的希望.
相关概念视频
Alzheimer's Disease: Overview
484
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
484
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K


